Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MYOK message board posts where the ticker symbol MYOK has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest MYOK SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001193125-18-172163 (34 Act)  Size: 255 KB
2018-05-23 001-37609
18855788
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-18-172138 (33 Act)  Size: 504 KB
2018-05-23 333-223526
18855707
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-18-169736 (33 Act)  Size: 504 KB
2018-05-21 333-223526
18850710
8-K  Documents Current report, item 8.01
Acc-no: 0001193125-18-168652 (34 Act)  Size: 21 KB
2018-05-21 001-37609
18848395
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-18-011870 (34 Act)  Size: 6 MB
2018-05-08 001-37609
18815127
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-18-011834 (34 Act)  Size: 230 KB
2018-05-08 001-37609
18814778
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000215457-18-005613 (34 Act)  Size: 12 KB
2018-05-08 005-89169
18813533
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-011725 Size: 16 KB
2018-05-07
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-011663 Size: 6 KB
2018-05-07
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001193125-18-118993 (34 Act)  Size: 246 KB
2018-04-17 001-37609
18757802
More MYOK SEC Filings


Related news from
Wed, 23 May 2018
00:05:00 +0000
MyoKardia Announces Pricing of Public Offering of Common Stock
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $49.00 per share, before underwriting discounts. MyoKardia anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and short-term and long-term investments, to fund research and development activities for its development programs, including, but not limited to, its planned Phase 3 EXPLORER-HCM clinical trial of mavacamten and its planned Phase 2 clinical trial of MYK-491, as well as its other ongoing and planned clinical trials for mavacamten and MYK-491, its ongoing preclinical, discovery and research programs and the expansion of its platform, and for working capital and other general corporate purposes.
Mon, 21 May 2018
20:01:00 +0000
MyoKardia Announces Proposed Public Offering of Common Stock
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering of 3,750,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase an additional 562,500 shares of common stock at the public offering price, less the underwriting discount.
Mon, 21 May 2018
11:30:00 +0000
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO 2 and NYHA Classification Improvements. Expected to Initiate in Second Quarter ...
Fri, 18 May 2018
23:07:09 +0000
Should You Buy MyoKardia Inc (NASDAQ:MYOK) At $50.55?
MyoKardia Inc (NASDAQ:MYOK), a pharmaceuticals company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGS. As aRead More...
Thu, 17 May 2018
17:39:46 +0000
Inspire Awards 2018: Mary Cranston on why women need to push back on stereotypes about leadership
Mary Cranston is now a director at Visa, CSAA, MyoKardia, Chemours and other organizations. She’s seen a lot of progress on diversity in the 25 years she’s sat on boards, but more work needs to be done, she says.
Thu, 10 May 2018
20:30:00 +0000
MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 10, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Thu, 10 May 2018
12:30:00 +0000
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., May 10, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Wed, 09 May 2018
18:35:26 +0000
Edited Transcript of MYOK earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 MyoKardia Inc Earnings Call
Tue, 08 May 2018
21:44:54 +0000
MyoKardia: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 50 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Tue, 08 May 2018
20:01:00 +0000
MyoKardia Reports First Quarter 2018 Financial Results
Company to Host Conference Call and Webcast Today at 4:30 p.m. ET. SOUTH SAN FRANCISCO, Calif., May 08, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine ...
Thu, 03 May 2018
20:01:00 +0000
MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018
SOUTH SAN FRANCISCO, Calif., May 03, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Mon, 09 Apr 2018
12:10:00 +0000
New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Wed, 04 Apr 2018
12:30:00 +0000
MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., April 04, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Mon, 02 Apr 2018
12:30:00 +0000
MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
SOUTH SAN FRANCISCO, Calif., April 02, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Fri, 16 Mar 2018
12:15:00 +0000
Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Fri, 09 Mar 2018
14:50:01 +0000
Edited Transcript of MYOK earnings conference call or presentation 8-Mar-18 9:30pm GMT
Q4 2017 MyoKardia Inc Earnings Call
Thu, 08 Mar 2018
22:28:32 +0000
MyoKardia reports 4Q loss
On a per-share basis, the South San Francisco, California-based company said it had a loss of 21 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
Thu, 08 Mar 2018
21:03:00 +0000
MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results
Announced Achievement of Primary Endpoint and Additional Key Data from Low-Dose Mavacamten Cohort of PIONEER-HCM Phase 2 Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy. Company to Host Conference ...
Thu, 08 Mar 2018
21:02:00 +0000
MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
Met Primary Endpoint and Key Secondary Endpoints with Statistical Significance. Study Results Inform Phase 3 EXPLORER-HCM Dosing; First Patient Planned for Q2 2018. Conference Call Today at 4:30 p.m. ET; ...
Thu, 08 Mar 2018
18:15:00 +0000
MyoKardia, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / MyoKardia, Inc. (NASDAQ: MYOK ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:30 PM Eastern Time. To ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is comprised of a large and growing, diverse, knowledgeable group of investors. The attribute you should appreciate that this wonderful group makes available to you as an incoming member is Generosity. Research, firsthand sector sophistication, source references and sometimes remarkably insightful analyses are given freely by the members so you may do your own due dilligence in making informed investment decisions." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards